Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | MRGPRX1 | Q96LB2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954551 | 1.00 | L3MBTL1 (0.42) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL9945923 | 0.89 | L3MBTL1 (0.44) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL31314076 | 0.86 | LIPE (0.36) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL29951322 | 0.86 | HTR2C (0.43) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL14988246 | 0.86 | HTR2C (0.43) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL29952296 | 0.85 | L3MBTL1 (0.42) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL1440694 | 0.85 | L3MBTL1 (0.42) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL29953495 | 0.84 | CYP1A2 (0.42) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL16034890 | 0.84 | CYP1A2 (0.42) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL5869062 | 0.82 | ENPP2 (0.40) | LIPEENPP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | ENANTA PHARM INC (US) | 2024-08-08 | — | — | US | disclosed |
| CN-117683020-A | Aminopyridine compound of phthalazinone, preparation method thereof and application thereof in preparation of inhibitor and antitumor drug | 华南理工大学 | 2024-03-12 | — | — | CN | disclosed |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| CN-117062607-A | Methyl substituted pyridine and pyridazine compounds, derivatives thereof and methods of use thereof | 拉堤果生物医疗股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230075366-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| CN-112079829-B | 1,2, 4-triazole [4,3-a ] pyridine derivative and preparation method and application thereof | 四川大学 | 2021-11-26 | — | — | CN | disclosed |
| EP-3883570-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| CN-112079829-A | 1,2, 4-triazole [4,3-a ] pyridine derivative and preparation method and application thereof | 四川大学 | 2020-12-15 | — | — | CN | disclosed |
| US-20140057911-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS | VIROSTATICS SRL (IT) | 2014-02-27 | — | — | US | disclosed |
| US-20140057911-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS | VIROSTATICS SRL (IT) | 2014-02-27 | — | — | US | disclosed |
| US-20140057911-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS | VIROSTATICS SRL (IT) | 2014-02-27 | — | — | US | disclosed |
| WO-2013037894-A1 | DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-21 | — | — | WO | disclosed |
| WO-2012129491-A1 | TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20120245124-A1 | TRPV3 Modulators | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
| EP-1773843-A4 | SMALL MOLECULE THIENOPYRIMIDINE-BASED PROTEIN TYROSINE KINASE INHIBITORS | UNIV TEXAS (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1773843-A1 | SMALL MOLECULE THIENOPYRIMIDINE-BASED PROTEIN TYROSINE KINASE INHIBITORS | The Board of Regents of The University of Texas System (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014404-A1 | SMALL MOLECULE THIENOPYRIMIDINE-BASED PROTEIN TYROSINE KINASE INHIBITORS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060004002-A1 | Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004002-A1 | Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors | SRC, LCK, FYN | L3MBTL1 1793/4885CYP1A2 4112/4885CYP2D6 3946/4885 |
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | HCCS, HAVCR2, HDGF | L3MBTL1 4720/4885CYP1A2 222/4885CYP2D6 276/4885 |
| US-20120245124-A1 | TRPV3 Modulators | TRPV3, TRPV2, TRPV1 | L3MBTL1 4623/4885CYP1A2 1842/4885CYP2D6 1796/4885 |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | L3MBTL1 4720/4885CYP1A2 222/4885CYP2D6 276/4885 |
| US-20140057911-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS | DPYD, ABL1, BRD4 | L3MBTL1 1612/4885CYP1A2 580/4885CYP2D6 32/4885 |
| US-20230075366-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | L3MBTL1 4720/4885CYP1A2 222/4885CYP2D6 276/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | L3MBTL1 4720/4885CYP1A2 222/4885CYP2D6 276/4885 |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | L3MBTL1 4720/4885CYP1A2 222/4885CYP2D6 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.